Arpad Szallasi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Arpad Szallasi has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Ferrer-Montiel
Instituto de Investigación, Desarrollo e Innovación en Biotecnología Sanitaria de Elche (IDiBE) Universidad Miguel Hernández de Elche Spain
1 shared publication Charles A. Blum
Merck co
1 shared publicationDaniel N. Cortright
1 shared publication- Delia Preti
University of Ferrara Via Luigi Borsari 46
1 shared publication Fanghong Li
Department of Pathology, Monmouth Medical Center, Long Branch, New Jersey
1 shared publication- Feng Qin
State University of New York at Buffalo
1 shared publication
Latest Publications
- Top Cited Papers
- 28 April 2014
- Published by Wiley in British Journal of Pharmacology
- Vol. 171 (10) , 2474-2507
Transient receptor potential (TRP) channels: a clinical perspective
Transient receptor potential (TRP) channels are important mediators of sensory signals with marked effects on cellular functions and signalling pathways. Indeed, mutations in genes encodingTRPchannels are the cause of several inherited diseases in humans (the so‐called ‘TRPchannelopathies’) that affect the cardiovascular, renal, skeletal and nervous systems.TRPchannels are also promising targets for drug discovery. The initial focus of research was onTRPchannels that are expressed on nociceptive neurons. Indeed, a number of potent, small‐moleculeTRPV1,TRPV3 andTRPA1 antagonists have already entered clinical trials as novel analgesic agents. There has been a recent upsurge in the amount of work that expandsTRPchannel drug discovery efforts into new disease areas such as asthma, cancer, anxiety, cardiac hypertrophy, as well as obesity and metabolic disorders. A better understanding ofTRPchannel functions in health and disease should lead to the discovery of first‐in‐class drugs for these intractable diseases. With this review, we hope to capture the current state of this rapidly expanding and changing field.Linked Articles: This article is part of a themed section on the pharmacology of TRP channels. To view the other articles in this section visithttp://dx.doi.org/10.1111/bph.2014.171.issue‐10
- 28 April 2014
- Published by Wiley in British Journal of Pharmacology
- Vol. 171 (10) , 2474-2507
Top Cited PapersTransient receptor potential (TRP) channels: a clinical perspective
Transient receptor potential (TRP) channels are important mediators of sensory signals with marked effects on cellular functions and signalling pathways. Indeed, mutations in genes encodingTRPchannels are the cause of several inherited diseases in humans (the so‐called ‘TRPchannelopathies’) that affect the cardiovascular, renal, skeletal and nervous systems.TRPchannels are also promising targets for drug discovery. The initial focus of research was onTRPchannels that are expressed on nociceptive neurons. Indeed, a number of potent, small‐moleculeTRPV1,TRPV3 andTRPA1 antagonists have already entered clinical trials as novel analgesic agents. There has been a recent upsurge in the amount of work that expandsTRPchannel drug discovery efforts into new disease areas such as asthma, cancer, anxiety, cardiac hypertrophy, as well as obesity and metabolic disorders. A better understanding ofTRPchannel functions in health and disease should lead to the discovery of first‐in‐class drugs for these intractable diseases. With this review, we hope to capture the current state of this rapidly expanding and changing field.Linked Articles: This article is part of a themed section on the pharmacology of TRP channels. To view the other articles in this section visithttp://dx.doi.org/10.1111/bph.2014.171.issue‐10
- 11 July 2012
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 21 (9) , 1351-1369
Targeting TRPV1 for pain relief: limits, losers and laurels
Introduction: With 336 reviews, the capsaicin receptor TRPV1 arguably represent today's most extensively reviewed analgesic target. TRPV1 is strategically located at the peripheral terminals of primary sensory neurons where pain is generated. TRPV1 as a target for analgesic drugs has been validated in preclinical studies. Areas covered: The therapeutic potential of targeting TRPV1 by agonists and antagonists for pain relief is discussed based on our experience and a critical review of the literature. Strategies to overcome adverse effects are explored. Expert opinion: Since its discovery in 1997, TRPV1 has run the gamut from excitement to disappointment to cautious optimism. Topical capsaicin has been disappointing for pain relief. By contrast, intrathecal resiniferatoxin is currently undergoing clinical trials in patients with intractable cancer pain. Some of the small-molecule TRPV1 antagonists have successfully passed Phase I safety and tolerability studies in healthy volunteers into Phase II studies to access efficacy in patients. Others showed worrisome unforeseen adverse effects, most important, hyperthermia and impaired noxious heat sensation. We conclude that TRPV1 blockade and desensitization are two promising, complimentary approaches for pain relief. Despite the roadblocks, TRPV1 remains a powerful tool in pain research and a promising therapeutic target.
- 11 July 2012
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 21 (9) , 1351-1369
Targeting TRPV1 for pain relief: limits, losers and laurels
Introduction: With 336 reviews, the capsaicin receptor TRPV1 arguably represent today's most extensively reviewed analgesic target. TRPV1 is strategically located at the peripheral terminals of primary sensory neurons where pain is generated. TRPV1 as a target for analgesic drugs has been validated in preclinical studies. Areas covered: The therapeutic potential of targeting TRPV1 by agonists and antagonists for pain relief is discussed based on our experience and a critical review of the literature. Strategies to overcome adverse effects are explored. Expert opinion: Since its discovery in 1997, TRPV1 has run the gamut from excitement to disappointment to cautious optimism. Topical capsaicin has been disappointing for pain relief. By contrast, intrathecal resiniferatoxin is currently undergoing clinical trials in patients with intractable cancer pain. Some of the small-molecule TRPV1 antagonists have successfully passed Phase I safety and tolerability studies in healthy volunteers into Phase II studies to access efficacy in patients. Others showed worrisome unforeseen adverse effects, most important, hyperthermia and impaired noxious heat sensation. We conclude that TRPV1 blockade and desensitization are two promising, complimentary approaches for pain relief. Despite the roadblocks, TRPV1 remains a powerful tool in pain research and a promising therapeutic target.
- 6 June 2012
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 22 (6) , 663-695
TRP channels as therapeutic targets in airway disorders: a patent review
Introduction: Chronic respiratory diseases, such as asthma and chronic obstructive pulmonary disease, affect millions of patients worldwide. New therapeutic approaches to these conditions are urgently needed since current treatment options provide only symptomatic relief. Transient receptor potential (TRP) ion channels are emerging molecular target candidates for the development of novel, disease-modifying drugs addressing airway diseases. Areas covered: The authors review the patent literature on novel molecules targeting TRP channels (in particular TRPA1, TRPV1, TRPM8 and TRPC6) that are currently studied in clinical trials or are candidates for future clinical evaluation in the management of respiratory diseases. Expert opinion: The patent literature highlights TRPA1 and TRPV1 channels as the most advanced therapeutic targets in respiratory disorders. TRPV1 antagonists relieve cough in preclinical studies. TRPA1 antagonists not only are anti-tussive but also show efficacy in allergic asthma models. How...
- 6 June 2012
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 22 (6) , 663-695
TRP channels as therapeutic targets in airway disorders: a patent review
Introduction: Chronic respiratory diseases, such as asthma and chronic obstructive pulmonary disease, affect millions of patients worldwide. New therapeutic approaches to these conditions are urgently needed since current treatment options provide only symptomatic relief. Transient receptor potential (TRP) ion channels are emerging molecular target candidates for the development of novel, disease-modifying drugs addressing airway diseases. Areas covered: The authors review the patent literature on novel molecules targeting TRP channels (in particular TRPA1, TRPV1, TRPM8 and TRPC6) that are currently studied in clinical trials or are candidates for future clinical evaluation in the management of respiratory diseases. Expert opinion: The patent literature highlights TRPA1 and TRPV1 channels as the most advanced therapeutic targets in respiratory disorders. TRPV1 antagonists relieve cough in preclinical studies. TRPA1 antagonists not only are anti-tussive but also show efficacy in allergic asthma models. How...
- 1 January 2012
- Vol. 10 (1) , 28-33
Blood management by transfusion triggers: when less is more
We reviewed the annual blood utilisation data at our institution for the past 6 years. The number of packed red blood cell units for allogeneic transfusions gradually increased from 3,989 (in 2004) to 4,762 (in 2008): a 19% increase. This exceeded the 7% increase in annual admissions of patients during the same period (from 20,470 in 2004 to 21,908 in 2005).MATERIALS AND METHODS:In 2009, we introduced new transfusion guidelines ("triggers"), essentially adopting the recommendations of the Society for the Advancement of Blood Management. Most importantly, we reduced the trigger of blood transfusions in normovolaemic symptomatic chronic anaemia patients from 8 to 7 g/dL haemoglobin. At the same time, we created a new trigger of 9 g/dL haemoglobin for high-risk patients (e.g. those with cardiovascular and/or chronic pulmonary disease as well as those undergoing chemotherapy).RESULTS:We monitored the indications for blood transfusions during 2009 (2,717 consecutive orders) and sent out letters of reminder of the new guidelines to our clinicians if criteria were not met (a total of 102 letters, representing 4% of the reviewed orders). Our annual blood utilisation in 2009 showed some improvement (4,648 units) compared to the previous year (4,762 units) despite the increase in admissions of patients (from 21,908 to 22,734): this represents a 6% decrease in blood utilisation when corrected for the admissions of patients. If this trends holds up, the predicted blood utilisation for 2010 based on the January to November data (4,280) promises to show a further improvement (an 11% decrease compared to 2008).DISCUSSION:We conclude that blood utilisation may be improved in a community hospital setting by combining new, evidence-based transfusion triggers with physicians' educatio
- 1 January 2012
- Vol. 10 (1) , 28-33
Blood management by transfusion triggers: when less is more
We reviewed the annual blood utilisation data at our institution for the past 6 years. The number of packed red blood cell units for allogeneic transfusions gradually increased from 3,989 (in 2004) to 4,762 (in 2008): a 19% increase. This exceeded the 7% increase in annual admissions of patients during the same period (from 20,470 in 2004 to 21,908 in 2005).MATERIALS AND METHODS:In 2009, we introduced new transfusion guidelines ("triggers"), essentially adopting the recommendations of the Society for the Advancement of Blood Management. Most importantly, we reduced the trigger of blood transfusions in normovolaemic symptomatic chronic anaemia patients from 8 to 7 g/dL haemoglobin. At the same time, we created a new trigger of 9 g/dL haemoglobin for high-risk patients (e.g. those with cardiovascular and/or chronic pulmonary disease as well as those undergoing chemotherapy).RESULTS:We monitored the indications for blood transfusions during 2009 (2,717 consecutive orders) and sent out letters of reminder of the new guidelines to our clinicians if criteria were not met (a total of 102 letters, representing 4% of the reviewed orders). Our annual blood utilisation in 2009 showed some improvement (4,648 units) compared to the previous year (4,762 units) despite the increase in admissions of patients (from 21,908 to 22,734): this represents a 6% decrease in blood utilisation when corrected for the admissions of patients. If this trends holds up, the predicted blood utilisation for 2010 based on the January to November data (4,280) promises to show a further improvement (an 11% decrease compared to 2008).DISCUSSION:We conclude that blood utilisation may be improved in a community hospital setting by combining new, evidence-based transfusion triggers with physicians' educatio
- 24 December 2010
- Published by Springer Nature
- Vol. 704, 491-515
Complex Regulation of TRPV1 and Related Thermo-TRPs: Implications for Therapeutic Intervention
The capsaicin receptor TRPV1 (Transient Receptor Potential, Vanilloid family member 1), the founding member of the heat-sensitive TRP (“thermo-TRP”) channel family, plays a pivotal role in pain transduction. There is mounting evidence that TRPV1 regulation is complex and is manifest at many levels, from gene expression through post-translational modification and formation of receptor heteromers to subcellular compartmentalization and association with regulatory proteins. These mechanisms are believed to be involved both in disease-related changes in TRPV1 expression, and the long-lasting refractory state, referred to as “desensitization”, that follows TRPV1 agonist treatment. The signaling cascades that regulate TRPV1 and related thermo-TRP channels are only beginning to be understood. Here we review our current knowledge in this rapidly changing field. We propose that the complex regulation of TRPV1 may be exploited for therapeutic purposes, with the ultimate goal being the development of novel, innovative agents that target TRPV1 in diseased, but not healthy, tissues. Such compounds are expected to be devoid of the side-effects (e.g. hyperthermia and impaired noxious heat sensation) that plague the clinical use of existing TRPV1 antagonists.
- 24 December 2010
- Published by Springer Nature
- Vol. 704, 491-515
Complex Regulation of TRPV1 and Related Thermo-TRPs: Implications for Therapeutic Intervention
The capsaicin receptor TRPV1 (Transient Receptor Potential, Vanilloid family member 1), the founding member of the heat-sensitive TRP (“thermo-TRP”) channel family, plays a pivotal role in pain transduction. There is mounting evidence that TRPV1 regulation is complex and is manifest at many levels, from gene expression through post-translational modification and formation of receptor heteromers to subcellular compartmentalization and association with regulatory proteins. These mechanisms are believed to be involved both in disease-related changes in TRPV1 expression, and the long-lasting refractory state, referred to as “desensitization”, that follows TRPV1 agonist treatment. The signaling cascades that regulate TRPV1 and related thermo-TRP channels are only beginning to be understood. Here we review our current knowledge in this rapidly changing field. We propose that the complex regulation of TRPV1 may be exploited for therapeutic purposes, with the ultimate goal being the development of novel, innovative agents that target TRPV1 in diseased, but not healthy, tissues. Such compounds are expected to be devoid of the side-effects (e.g. hyperthermia and impaired noxious heat sensation) that plague the clinical use of existing TRPV1 antagonists.
- 25 August 2010
- Published by Wiley in Vox Sanguinis
- Vol. 100 (3) , 298-302
‘Wrong blood in tube’: solutions for a persistent problem
Background and Objectives This study was performed to determine the incidence of ‘wrong blood in tube’ (WBIT)‐type errors at our institution during the past 5 years, to analyse their root cause and to evaluate the efficacy of preventive measures that have been implemented since 2006.Methods All reports of mislabelled and miscollected specimens detected between January 2005 and December 2009 were reviewed. Of these, WBIT‐type errors were further analysed as they represent a major risk for mistransfusion.Results Between 2005 and 2009, 59 373 type and screens were performed at our institution and a total of 26 major errors (WBIT) were identified. Of the errors, eight were detected by discrepant typing results (in comparison with historic blood type), six were discovered by the clinical service and 12 were identified in the blood bank by other means. Our estimated ‘raw’ WBIT rate (1 in 2283 samples) is comparable to that (1:2262) in the published literature. Since 2006, our nursing policy mandates that ‘all type, screen and cross will have two witnesses to the correct ID of the patient and labeling is done at the bedside at the time of the draw.’ This has reduced (from 11 in 2006 to 5 in 2007), but did not eliminate, our WBIT problem that persisted into 2008 and 2009 (three and seven incidents, respectively). Since 2009, we also require a second, independently drawn sample in previously un‐typed patients who are likely to be transfused.Conclusion We conclude that WBITs continue to represent a leading cause of potential mistransfusions at our institution. Changes in nursing (two witnesses to correct ID) and/or blood bank policy (check‐type with a second specimen) may reduce, but not eliminate, this persistent problem. Clearly, additional safety measures are required to prevent WBIT‐type errors.
- 25 August 2010
- Published by Wiley in Vox Sanguinis
- Vol. 100 (3) , 298-302
‘Wrong blood in tube’: solutions for a persistent problem
Background and Objectives This study was performed to determine the incidence of ‘wrong blood in tube’ (WBIT)‐type errors at our institution during the past 5 years, to analyse their root cause and to evaluate the efficacy of preventive measures that have been implemented since 2006.Methods All reports of mislabelled and miscollected specimens detected between January 2005 and December 2009 were reviewed. Of these, WBIT‐type errors were further analysed as they represent a major risk for mistransfusion.Results Between 2005 and 2009, 59 373 type and screens were performed at our institution and a total of 26 major errors (WBIT) were identified. Of the errors, eight were detected by discrepant typing results (in comparison with historic blood type), six were discovered by the clinical service and 12 were identified in the blood bank by other means. Our estimated ‘raw’ WBIT rate (1 in 2283 samples) is comparable to that (1:2262) in the published literature. Since 2006, our nursing policy mandates that ‘all type, screen and cross will have two witnesses to the correct ID of the patient and labeling is done at the bedside at the time of the draw.’ This has reduced (from 11 in 2006 to 5 in 2007), but did not eliminate, our WBIT problem that persisted into 2008 and 2009 (three and seven incidents, respectively). Since 2009, we also require a second, independently drawn sample in previously un‐typed patients who are likely to be transfused.Conclusion We conclude that WBITs continue to represent a leading cause of potential mistransfusions at our institution. Changes in nursing (two witnesses to correct ID) and/or blood bank policy (check‐type with a second specimen) may reduce, but not eliminate, this persistent problem. Clearly, additional safety measures are required to prevent WBIT‐type errors.
- 13 February 2010
- Published by Springer Nature
- Vol. 617, 155-157
Human Correlates of Animal Models of Chronic Pain
Neuropathic pain is defined by International Association for the Study of Pain as “pain initiated or caused by a primary lesion or dysfunction in the nervous system which can persist long after the initial injury has healed”. Given the complexity of neuropathic pain (“lesion or dysfunction” encompasses a wide variety of disease states, ranging from trauma through neurotoxins and infections to metabolic disturbances), it is hardly surprising that an array of models has been developed for this pain condition, many of which are described in this volume. This chapter addresses the clinical correlates of these pain models.
- 13 February 2010
- Published by Springer Nature
- Vol. 617, 155-157
Human Correlates of Animal Models of Chronic Pain
Neuropathic pain is defined by International Association for the Study of Pain as “pain initiated or caused by a primary lesion or dysfunction in the nervous system which can persist long after the initial injury has healed”. Given the complexity of neuropathic pain (“lesion or dysfunction” encompasses a wide variety of disease states, ranging from trauma through neurotoxins and infections to metabolic disturbances), it is hardly surprising that an array of models has been developed for this pain condition, many of which are described in this volume. This chapter addresses the clinical correlates of these pain models.
- 12 February 2010
- Published by Wiley
- p. 68-100
Role of TRP Channels in Pain: An Overview
- 1 July 2008
- Published by Wiley in British Journal of Pharmacology
- Vol. 154 (5) , 915-917
Rimonabant in rats with a metabolic syndrome: good news after the depression
- 1 July 2008
- Published by Wiley in British Journal of Pharmacology
- Vol. 154 (5) , 915-917
Rimonabant in rats with a metabolic syndrome: good news after the depression
- 1 April 2008
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 16 (2) , 222-225
Wolffian Tumor of the Ovary With a Prominent Spindle Cell Component: Report of a Case With Brief Discussion of Unusual Problems in Differential Diagnosis, and Literature Review
An 87-year-old woman underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy for endometrioid adenocarcinoma. At operation, a 4.5-cm partially solid and partially cystic right ovarian mass was identified. Frozen section showed a cytologically bland spindle cell proliferation reminiscent of cellular fibroma. Extensive sampling of the ovarian mass revealed a focus with the classic sieve-like pattern of a Wolffian adnexal tumor that merged with the fibroma-like appearance. The uterus showed well-differentiated, superficially invasive endometrioid adenocarcinoma arising in a background of atypical complex hyperplasia. Given the recent reports implying a therapeutic value for Gleevec (Novartis, Stein, Switzerland) (STI-571) in the treatment of Wolffian tumor of the ovary, paraffin immunostain for CD117 (c-kit) was performed that yielded negative results. Without further therapy, the patient was alive without disease 7 months after surgery. This case demonstrates the heterogeneity of Wolffian tumor of the ovary and shows how crucial sampling is in arriving at the correct diagnosis.
- 1 April 2008
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 16 (2) , 222-225
Wolffian Tumor of the Ovary With a Prominent Spindle Cell Component: Report of a Case With Brief Discussion of Unusual Problems in Differential Diagnosis, and Literature Review
An 87-year-old woman underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy for endometrioid adenocarcinoma. At operation, a 4.5-cm partially solid and partially cystic right ovarian mass was identified. Frozen section showed a cytologically bland spindle cell proliferation reminiscent of cellular fibroma. Extensive sampling of the ovarian mass revealed a focus with the classic sieve-like pattern of a Wolffian adnexal tumor that merged with the fibroma-like appearance. The uterus showed well-differentiated, superficially invasive endometrioid adenocarcinoma arising in a background of atypical complex hyperplasia. Given the recent reports implying a therapeutic value for Gleevec (Novartis, Stein, Switzerland) (STI-571) in the treatment of Wolffian tumor of the ovary, paraffin immunostain for CD117 (c-kit) was performed that yielded negative results. Without further therapy, the patient was alive without disease 7 months after surgery. This case demonstrates the heterogeneity of Wolffian tumor of the ovary and shows how crucial sampling is in arriving at the correct diagnosis.